Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Can't Be More Risky. Short Interest Increased

Wall Street analysts are predicting that Adamis Pharmaceuticl (NASDAQ:ADMP) will report earnings per share of $-0.15 in their quarterly report.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) reported its EPS in the last quarter as $-0.21/Share lagging the analyst estimate of $-0.16/Share by a difference of $-0.05. The firm earned "Buy" rating on Monday, June 12 by Maxim Group. Finally, Raymond James Financial initiated coverage on shares of Adamis Pharmaceuticals in a report on Tuesday, September 12th.

Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections.

Boris Johnson blames 'crack cocaine of jihadi terrorism' on repressive states
The Foreign Secretary will say the West needs to realise that hundreds of millions of Muslims are on its side in the battle against terrorism.

Additionally on 12/20/16 B. Riley "Initiates Coverage On" Adamis Pharmaceuticl (NASDAQ:ADMP) to Buy setting price target at $5 and on 12/01/15 Maxim Group "Initiates Coverage on" the stock to Buy at $16. It would be unreasonable to assume the market for naloxone agents could increase some 50%- 75% prior to an ADMP approval creating a potential significant new growth avenue for the company. ValuEngine lowered shares of Adamis Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, October 3rd. With a return potential of 107%, the stock's consensus target price stands at $9.83.

As such, Wilbur reiterates an Outperform rating on Adamis shares with a price target of $7.00, which implies an upside of 48% from current levels.

In terms of Buy, Sell or Hold recommendations, Adamis Pharmaceuticl (NASDAQ:ADMP) has analysts' mean recommendation of 2. Two research analysts have rated the stock with a sell rating and three have issued a buy rating to the company. Adamis Pharmaceuticals now has a consensus rating of "Hold" and a consensus price target of $10.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.93 and a quick ratio of 3.79.

Câmara aprova lei que aumenta pena para motorista alcoolizado que causar morte
A lei atual prevê detenção de 2 a 4 anos e, dependendo da situação, o suspeito pode responder pelo crime em liberdade. O texto original da Câmara, aprovado em setembro de 2015, estabelecia pena de detenção de dois a quatro anos.

Large investors have recently bought and sold shares of the company.

Adamis Pharmaceuticl (NASDAQ:ADMP) has average revenue estimates of $4.05 Million, compared to low analyst estimates of $3.6 Million and high estimates of $4.5 Million for the current quarter. Advisor Group Inc. grew its stake in shares of Adamis Pharmaceuticals by 149.9% in the 3rd quarter. EAM Investors LLC now owns 371,732 shares of the specialty pharmaceutical company's stock valued at $1,942,000 after acquiring an additional 136,970 shares in the last quarter. Bank of New York Mellon Corp now owns 27,464 shares of the specialty pharmaceutical company's stock worth $143,000 after purchasing an additional 15,577 shares during the last quarter. Finally, Sterling Global Strategies LLC grew its position in Adamis Pharmaceuticals by 66.5% in the 2nd quarter. Leisure Capital Management now owns 145,909 shares of the specialty pharmaceutical company's stock worth $759,000 after purchasing an additional 9,832 shares in the last quarter. If you are reading this news story on another site, it was stolen and reposted in violation of USA and global copyright and trademark laws.

Adamis Pharmaceuticals Corporation is a pharmaceutical company. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments.

Bitcoin Surpasses $14000 Mark on Thursday, as S. Korea Rally Continues
An official from the securities industry said, "It is the first time for the South Korean authorities to ban trading a specific item".

Últimas notícias